First-line pembrolizumab plus chemotherapy prolonged survival among patients with advanced esophageal or esophagogastric junction cancer.
Nivolumab plus chemotherapy prolonged survival of patients with advanced gastric, gastroesophageal junction, and esophageal cancers compared with chemotherapy.
Genomic copy number instability predicted the risk of disease progression among patients with Barrett esophagus years beforehand.
The designation was based on results from Part A of a double-blind, placebo-controlled, pivotal phase 3 trial.
Results of a multicenter, retrospective study of per-oral endoscopic myotomy (POEM) for EGJOO suggest that POEM is an effective and safe therapy.
Patients undergoing sleeve gastrectomy sometimes develop gastroesophageal reflux disease, a major risk factor for Barrett’s esophagus; therefore, researchers investigated whether patients with SG have a high rate of BE.
This phase 3 trial examined whether budesonide orodispersible tablets (0.5 mg or 1 mg, twice daily), with ≤48 weeks of treatment, was superior to placebo in maintaining remission of eosinophilic esophagitis.
Time to rebleeding was a significant predictor of mortality risk following an endoscopic variceal ligation procedure.
Periodontal disease and tooth loss, indicative of oral microbial dysbiosis, are associated with esophageal and gastric adenocarcinoma.
PPIs are frequently used off-label and are easily accessible as over-the-counter products, contributing to the potential for adverse events or drug-drug interactions.
A team of investigators assessed the ability of the intraprocedural functional lumen imaging probe to measure cricopharyngeal distensibility in patients undergoing endoscopy cricopharyngeal myotomy for Zenker diverticulum.
Post-procedural esophagram may be insufficient to diagnose serious adverse events in patients who underwent peroral endoscopic myotomy (POEM).
High sarcopenia levels appear to be negatively associated with overall survival in male patients with esophageal carcinoma treated with upfront chemoradiotherapy.
Use of a 30 mm hydrostatic balloon dilator (EsoFLIP-330) was safe in treating patients with esophageal motility disorders and was most effective in those with achalasia.
Patients treated with non-vitamin K antagonist oral anticoagulants (NOACs) following atrial fibrillation were more likely to develop gastrointestinal bleeding and malignancies.
In a study of kidney transplant recipients, PPI users had an almost 2-fold increased risk of mortality compared with nonusers.
The FDA has approved Opdivo® (nivolumab; Bristol Myers Squibb) for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.
Dupilumab was associated with clinical and anatomic improvements in patients with eosinophilic esophagitis, according to results from a pivotal phase 3 study.
The prevalence of pediatric eosinophilic esophagitis (EoE) may be lower among children living in impoverished areas compared with others.
Proton pump inhibition therapy is suggested over no treatment for patients with symptomatic esophageal eosinophilia.